JP2024513514A5 - - Google Patents

Info

Publication number
JP2024513514A5
JP2024513514A5 JP2023562500A JP2023562500A JP2024513514A5 JP 2024513514 A5 JP2024513514 A5 JP 2024513514A5 JP 2023562500 A JP2023562500 A JP 2023562500A JP 2023562500 A JP2023562500 A JP 2023562500A JP 2024513514 A5 JP2024513514 A5 JP 2024513514A5
Authority
JP
Japan
Prior art keywords
cells
population
natural killer
combination
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023562500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023676 external-priority patent/WO2022216826A1/en
Publication of JP2024513514A publication Critical patent/JP2024513514A/ja
Publication of JP2024513514A5 publication Critical patent/JP2024513514A5/ja
Withdrawn legal-status Critical Current

Links

JP2023562500A 2021-04-08 2022-04-06 Ｎｋ細胞およびｃｄ３８－標的抗体を用いた癌治療 Withdrawn JP2024513514A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172424P 2021-04-08 2021-04-08
US63/172,424 2021-04-08
US202163290351P 2021-12-16 2021-12-16
US63/290,351 2021-12-16
PCT/US2022/023676 WO2022216826A1 (en) 2021-04-08 2022-04-06 Treatment of cancer with nk cells and a cd38-targeted antibody

Publications (2)

Publication Number Publication Date
JP2024513514A JP2024513514A (ja) 2024-03-25
JP2024513514A5 true JP2024513514A5 (cg-RX-API-DMAC10.html) 2025-04-14

Family

ID=83546555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562500A Withdrawn JP2024513514A (ja) 2021-04-08 2022-04-06 Ｎｋ細胞およびｃｄ３８－標的抗体を用いた癌治療

Country Status (6)

Country Link
US (1) US20240115704A1 (cg-RX-API-DMAC10.html)
EP (1) EP4319770A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024513514A (cg-RX-API-DMAC10.html)
KR (1) KR20240024047A (cg-RX-API-DMAC10.html)
AU (1) AU2022253256A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022216826A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
MX2016002970A (es) 2013-09-06 2016-10-07 Aurigene Discovery Tech Ltd Compuestos peptidomimeticos ciclicos como inmunomoduladores.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
WO2016142894A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ 免疫調節剤としての１，３，４−オキサジアゾールおよびチアジアゾール化合物
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882833B2 (en) 2016-05-23 2021-01-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018026971A1 (en) 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
WO2019008154A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3- (AZOLYLMETHOXY) BIPHENYL DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
WO2019008152A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3-CYANOTHIOPHENE DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3697500A1 (en) 2017-10-18 2020-08-26 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
WO2019201629A1 (en) * 2018-04-19 2019-10-24 Onkimmune Limited Nk cells for use with antibodies in cancer therapy
CN112839666A (zh) 2018-05-14 2021-05-25 因达普塔治疗公司 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
CN120501855A (zh) 2019-05-14 2025-08-19 赛诺菲-安万特美国有限责任公司 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Similar Documents

Publication Publication Date Title
JP2024513958A5 (cg-RX-API-DMAC10.html)
Shimasaki et al. NK cells for cancer immunotherapy
KR102883631B1 (ko) 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
JP7575104B2 (ja) ナチュラルキラー細胞およびキメラ抗原受容体改変された細胞の拡大増殖
JP2024513522A5 (cg-RX-API-DMAC10.html)
Rezvani et al. The application of natural killer cell immunotherapy for the treatment of cancer
JP2024515169A5 (cg-RX-API-DMAC10.html)
Giang et al. Nanoparticles engineered as artificial antigen-presenting cells induce human CD4+ and CD8+ Tregs that are functional in humanized mice
Wei et al. Chimeric antigen receptor T-cell therapy for T-ALL and AML
Omer et al. Enhancing natural killer cell targeting of pediatric sarcoma
EP4062920A1 (en) Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product
Fang et al. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
WO2019206326A1 (zh) 改进的t细胞治疗方法
JP2024541081A (ja) 低下したｔｇｆ－ベータ受容体シグナル伝達を有する遺伝子操作されたｔ細胞
Messaoudene et al. Patient’s natural killer cells in the era of targeted therapies: role for tumor killers
CA3249498A1 (en) ALLOGENIC T LYMPHOCYTES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
Beelen et al. Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy
JP2022023136A5 (cg-RX-API-DMAC10.html)
US20250375524A1 (en) Combination of engineered natural killer (nk) cells and antibody therapy and related methods
Peng et al. A cultured malignant B-1 line serves as a model for Richter's syndrome.
Zhang et al. Paving the way towards universal chimeric antigen receptor therapy in cancer treatment: current landscape and progress
CN114929865A (zh) 作为过继细胞疗法的基因工程化双阴性t细胞
CN119095953A (zh) 细胞表面受体的表位工程
EP3228701A1 (en) Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof